1. Home
  2. CMMB vs TENX Comparison

CMMB vs TENX Comparison

Compare CMMB & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • TENX
  • Stock Information
  • Founded
  • CMMB 2004
  • TENX 1967
  • Country
  • CMMB Israel
  • TENX United States
  • Employees
  • CMMB N/A
  • TENX N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • TENX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMMB Health Care
  • TENX Health Care
  • Exchange
  • CMMB Nasdaq
  • TENX Nasdaq
  • Market Cap
  • CMMB N/A
  • TENX 19.5M
  • IPO Year
  • CMMB N/A
  • TENX N/A
  • Fundamental
  • Price
  • CMMB $1.68
  • TENX $5.61
  • Analyst Decision
  • CMMB Strong Buy
  • TENX Strong Buy
  • Analyst Count
  • CMMB 3
  • TENX 4
  • Target Price
  • CMMB $7.33
  • TENX $20.67
  • AVG Volume (30 Days)
  • CMMB 87.3K
  • TENX 67.4K
  • Earning Date
  • CMMB 11-14-2024
  • TENX 11-13-2024
  • Dividend Yield
  • CMMB N/A
  • TENX N/A
  • EPS Growth
  • CMMB N/A
  • TENX N/A
  • EPS
  • CMMB N/A
  • TENX N/A
  • Revenue
  • CMMB N/A
  • TENX N/A
  • Revenue This Year
  • CMMB N/A
  • TENX N/A
  • Revenue Next Year
  • CMMB N/A
  • TENX N/A
  • P/E Ratio
  • CMMB N/A
  • TENX N/A
  • Revenue Growth
  • CMMB N/A
  • TENX N/A
  • 52 Week Low
  • CMMB $0.45
  • TENX $2.77
  • 52 Week High
  • CMMB $2.55
  • TENX $27.36
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 52.44
  • TENX 54.30
  • Support Level
  • CMMB $1.53
  • TENX $5.70
  • Resistance Level
  • CMMB $1.71
  • TENX $6.01
  • Average True Range (ATR)
  • CMMB 0.11
  • TENX 0.47
  • MACD
  • CMMB -0.01
  • TENX -0.08
  • Stochastic Oscillator
  • CMMB 39.47
  • TENX 12.15

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: